[go: up one dir, main page]

DK0642577T3 - Antistoffer med specificitet for multiple adhæsionsmolekyler - Google Patents

Antistoffer med specificitet for multiple adhæsionsmolekyler

Info

Publication number
DK0642577T3
DK0642577T3 DK93915132T DK93915132T DK0642577T3 DK 0642577 T3 DK0642577 T3 DK 0642577T3 DK 93915132 T DK93915132 T DK 93915132T DK 93915132 T DK93915132 T DK 93915132T DK 0642577 T3 DK0642577 T3 DK 0642577T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibodies
antibodies
adhesion molecules
selectins
selectin
Prior art date
Application number
DK93915132T
Other languages
Danish (da)
English (en)
Inventor
Mark A Jutila
Original Assignee
Univ Montana State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Montana State filed Critical Univ Montana State
Application granted granted Critical
Publication of DK0642577T3 publication Critical patent/DK0642577T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK93915132T 1992-05-22 1993-05-21 Antistoffer med specificitet for multiple adhæsionsmolekyler DK0642577T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88769592A 1992-05-22 1992-05-22
US6450593A 1993-05-19 1993-05-19

Publications (1)

Publication Number Publication Date
DK0642577T3 true DK0642577T3 (da) 2004-07-19

Family

ID=26744587

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93915132T DK0642577T3 (da) 1992-05-22 1993-05-21 Antistoffer med specificitet for multiple adhæsionsmolekyler

Country Status (12)

Country Link
US (1) US5756095A (fr)
EP (2) EP0642577B1 (fr)
JP (1) JP3512111B2 (fr)
KR (1) KR950701681A (fr)
AT (1) ATE261493T1 (fr)
AU (1) AU682824B2 (fr)
CA (1) CA2134966C (fr)
DE (1) DE69333447T2 (fr)
DK (1) DK0642577T3 (fr)
ES (1) ES2213141T3 (fr)
PT (1) PT642577E (fr)
WO (1) WO1993024614A1 (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5622701A (en) * 1994-06-14 1997-04-22 Protein Design Labs, Inc. Cross-reacting monoclonal antibodies specific for E- and P-selectin
US8128963B2 (en) 1996-09-27 2012-03-06 The Trustees Of Columbia University In The City Of New York Methods for treating ischemic disorders using carbon monoxide
DK0951292T3 (da) * 1996-09-27 2007-08-13 Univ Columbia Behandling af en iskæmisk lidelse og forbedring af udfald af slagtilfælde
WO1998033526A1 (fr) * 1997-02-03 1998-08-06 Sumitomo Pharmaceuticals Company, Limited Remedes contre la cardiomyopathie
AU2322099A (en) * 1998-01-16 1999-08-02 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
AU2007202323C1 (en) * 2000-06-29 2012-04-12 Abbvie Inc. Dual specificity antibodies and methods of making and using
DE60137421D1 (de) * 2000-06-29 2009-03-05 Abbott Lab Antikörper mit zwei spezifizitäten und verfahren zur deren herstellung und verwendung
WO2006083322A2 (fr) * 2004-07-29 2006-08-10 Ligocyte Pharmaceuticals, Inc. Methodes de traitement et de prevention d'infections a l'aide d'agents anti-selectine
EP2267030A1 (fr) 2005-08-25 2010-12-29 Repair Technologies, Inc. Dispositifs, compositions et méthodes de protection et de réparation de cellules et de tissus
US7998740B2 (en) * 2006-07-18 2011-08-16 Robert Sackstein Cytokine induction of selectin ligands on cells
WO2008082651A2 (fr) * 2006-12-29 2008-07-10 Abbott Laboratories Anticorps il-1a/il-1b à double spécificité
WO2009079585A2 (fr) 2007-12-17 2009-06-25 Dyax Corp. Compositions et procédés pour traiter des troubles ostéolytiques comprenant des protéines de liaison à mmp-14
WO2010054393A1 (fr) * 2008-11-10 2010-05-14 Mount Sinai School Of Medicine Of New York University Méthodes de réduction des lésions tissulaires associées à l’inflammation en inhibant l’activité des neutrophiles
CA2754635C (fr) * 2009-03-06 2018-06-19 Universite Paris Descartes Utilisation de milieu conditionne au fibroplaste gingival en vue de traiter un cancer metastasique
TW201124535A (en) * 2009-10-30 2011-07-16 Abbott Lab SORF constructs and multiple gene expression
US10314909B2 (en) 2011-10-21 2019-06-11 Dyax Corp. Combination therapy comprising an MMP-14 binding protein
JP5865009B2 (ja) * 2011-10-25 2016-02-17 シスメックス株式会社 活性化好中球の検出方法
EP3515948A4 (fr) 2016-09-23 2020-04-08 CSL Limited Protéines de liaison au facteur de coagulation et leurs utilisations
EP4093508A1 (fr) 2020-01-24 2022-11-30 Pfizer Inc. Anticorps anti-e-sélectine, compositions et procédés d'utilisation

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2606033B1 (fr) * 1986-10-31 1988-12-16 Cird Proteine cytoplasmique des cellules suprabasales de l'epiderme, anticorps capables de reconnaitre cette proteine, et lignees cellulaires hybrides capables de secreter de tels anticorps
US4849509A (en) * 1987-02-20 1989-07-18 The Wistar Institute Monoclonal antibodies against melanoma-associated antigens and hybrid cell lines producing these antibodies
US4935234A (en) * 1987-06-11 1990-06-19 Dana-Farber Cancer Institute Method of reducing tissue damage at an inflammatory site using a monoclonal antibody
US5019648A (en) * 1987-07-06 1991-05-28 Dana-Farber Cancer Institute Monoclonal antibody specific for the adhesion function domain of a phagocyte cell surface protein
US5071964A (en) * 1988-05-04 1991-12-10 Dana-Farber Cancer Institute, Inc. Protein micelles
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
US5098833A (en) 1989-02-23 1992-03-24 Genentech, Inc. DNA sequence encoding a functional domain of a lymphocyte homing receptor
US5002873A (en) * 1989-03-17 1991-03-26 Fred Hutchinson Cancer Research Center DNA sequence encoding a lymphocyte adhesion receptor for high endothelium
US5011778A (en) * 1989-05-23 1991-04-30 Otsuka Pharmaceutical Co., Ltd. Monoclonal antibodies directed to IL-1 activated endothelial cells and medicaments employing the monoclonal antibodies
US5080883A (en) * 1990-05-11 1992-01-14 Mallinckrodt, Inc. 99 mtcn3s-conjugated anti-bibrin monoclonal antibody as an in vivo diagnostic agent for imaging

Also Published As

Publication number Publication date
ATE261493T1 (de) 2004-03-15
KR950701681A (ko) 1995-04-28
ES2213141T3 (es) 2004-08-16
JPH08502242A (ja) 1996-03-12
CA2134966C (fr) 2007-03-27
EP1340811A2 (fr) 2003-09-03
CA2134966A1 (fr) 1993-12-09
DE69333447T2 (de) 2009-09-10
DE69333447D1 (de) 2004-04-15
PT642577E (pt) 2004-08-31
AU682824B2 (en) 1997-10-23
WO1993024614A1 (fr) 1993-12-09
EP1340811A3 (fr) 2003-11-19
EP0642577B1 (fr) 2004-03-10
EP0642577A1 (fr) 1995-03-15
EP0642577A4 (en) 1995-04-12
AU4523293A (en) 1993-12-30
US5756095A (en) 1998-05-26
JP3512111B2 (ja) 2004-03-29

Similar Documents

Publication Publication Date Title
DK0642577T3 (da) Antistoffer med specificitet for multiple adhæsionsmolekyler
NO159888C (no) Monoklonalt antistoff.
FI852029A0 (fi) Maenniskans monoklonala antikroppar mot serotypiska lipopolysackariddeterminanter av gram- negativa bakterier samt deras framstaellning.
AU6600181A (en) Hybrid cell line
HU9603387D0 (en) Monoclonal antibody active against cd44v6
JPS6413992A (en) Hybridoma
EP0141079A3 (en) Monoclonal antibodies specific for membrane-associated antigens
CA2227548A1 (fr) Anticorps monoclonal humain dirige contre l'antigene de surface du virus de l'hepatite b
EP0212403A3 (fr) Anticorps monoclonaux contre des antigènes humains de différenciation du genre mucine
JPS6463376A (en) Hybridmer
JPS6413991A (en) Hybridoma
CA2316411A1 (fr) Anticorps humanises monoclonaux protegeant contre les maladies induites par les toxines de shiga
ES2000615A6 (es) Procedimiento para la preparacion del anticuerpo monoclonal designado como mak 436-15 del isotipo igg3"
CA2145005A1 (fr) Anticorps monoclonal specifique pour le tcf-ii
AU3283693A (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
MX9606108A (es) Anticuerpos monoclonales contra cd44v6.
IT8120249A0 (it) Lamiere di acciaio al silicio non orientato, dotate di proprieta'magnetiche stabili.
JPS5368013A (en) Answer display transfer system for charging trunk additional unit